Evidence map›Paper›PMID 40627176›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025

The African-Specific Variant in the Duffy Antigen Receptor for Chemokines Gene, CD8+ T-Cell Density, and Aggressive Breast Cancer Subtypes in Black Women.

Nisha M Nair, Lucas Mendicino, Peter N Fiorica, Angela R Omilian, Thaer Khoury, Wiam Bshara, Elisa V Bandera, Chi-Chen Hong, Yara Abdou, Jo L Freudenheim and 14 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Nisha M NairDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0009-0008-8567-3314
Lucas MendicinoDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0009-0002-8116-5298
Peter N FioricaDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-1001-1518
Angela R OmilianDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0001-6348-9411
Thaer KhouryDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-8112-6590
Wiam BsharaDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0003-3238-1664
Elisa V BanderaCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, Brunswick, New Jersey.ORCID 0000-0002-8789-2755
Chi-Chen HongDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0001-9212-2264
Yara AbdouDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-4827-8613
Jo L FreudenheimDepartment of Epidemiology and Environmental Health, State University of New York at Buffalo, Buffalo, New York.ORCID 0000-0002-9301-0499
Anselm J M HennisDepartment of Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, District of Columbia.ORCID 0009-0004-0005-7979
Katie M O'BrienBiostatistics and Computational Biology Branch, NIEHS, Research Triangle Park, North Carolina.ORCID 0000-0002-1931-1349
Gary R ZirpoliSlone Epidemiology Center, Boston University, Boston, Massachusetts.ORCID 0000-0003-1417-5349
Ebonee N ButlerDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-4638-1190
John Oladapo ObafunwaDepartment of Pathology and Forensic Medicine, Lagos State University Teaching Hospital, Lagos, Nigeria.ORCID 0000-0001-6014-168X
Clarice R WeinbergBiostatistics and Computational Biology Branch, NIEHS, Research Triangle Park, North Carolina.ORCID 0000-0002-7713-8556
Dezheng HuoDepartment of Public Health Sciences, The University of Chicago, Chicago, Illinois.ORCID 0000-0002-4041-1678
Bingshan LiDepartment of Molecular Physiology & Biophysics, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, Tennessee.ORCID 0000-0003-2129-168X
Xingyi GuoDepartment of Medicine, Vanderbilt University, Nashville, Tennessee.ORCID 0000-0001-5269-1294
Julie R PalmerSlone Epidemiology Center, Boston University, Boston, Massachusetts.ORCID 0000-0002-6534-335X
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, California.ORCID 0000-0002-0097-9971
Wei ZhengDepartment of Medicine, Vanderbilt University, Nashville, Tennessee.ORCID 0000-0003-1226-070X
Song YaoDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0001-9442-1313
Christine B AmbrosoneDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0003-1717-9943

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Reproduction, Lactation and Hormonal Factors in Breast Cancer SubtypesP01CA151135 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B., OLSHAN, ANDREW · 2011 to 2017
$18.1M
Breast Cancer genetic study in African-ancestry populationsR01CA202981 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Wei Zheng · 2016 to 2026
$14.1M
Obesity, related comorbidities, and breast cancer outcomes in African AmericansR01CA185623 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI BANDERA, ELISA V, DEMISSIE, KITAW · 2014 to 2018
$6.2M
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European AncestryR01CA247281 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I., AMBROSONE, CHRISTINE B. · 2020 to 2024
$5.2M
Breast Cancer Research Foundation (BCRF)Intramural NIH HHS Z99 ES999999National Cancer Institute (NCI) P30 CA16056National Cancer Institute (NCI) R01 CA10059National Cancer Institute (NCI) R01 CA225948National Cancer Institute (NCI) R01 CA247282NCI NIH HHS P01 CA151135NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA185623NCI NIH HHS R01 CA202981NCI NIH HHS R01 CA247281
6 · The paper itself

Abstract

backgroundImmune response in blood varies by ancestry, linked to an African-specific variant (rs2814778) in the Duffy Antigen Receptor for Chemokines (DARC/ACKR1) gene. We examined associations between rs2814778, CD8+ T-cell density in breast tumors, and breast cancer risk in African-American/Black women.

methodsCD8+ T-cell density in tumors from 428 Black women were examined in relation to the rs2814778 variant. In the African Ancestry Breast Cancer Genetics (AABCG) Consortium with 16,886 cases and 18,044 controls, rs2814778 was evaluated in relation to risk of overall breast cancer and to more aggressive subtypes [estrogen receptor-negative (ER-) and triple-negative breast cancer (TNBC)].

resultsWomen with the African-specific CC genotype had lower tumor CD8+ T-cell density (87.0 per mm2) than those with TT genotypes (146.6 per mm2; P < 0.05). Each T allele was significantly associated with an increase in T-cell density (P = 0.04). In the largest analysis, to date, there were no associations between rs2814778 and risk of overall breast cancer [OR = 0.90 (95% confidence interval (CI), 0.66-1.22)] or with ER- breast cancer [OR = 0.86 (95% CI, 0.68-1.08)] or TNBC [OR = 0.77 (95% CI, 0.56-1.05)].

conclusionsAlthough breast tumors from women with the African-specific DARCC allele had lower CD8+ T-cell density levels than those with T alleles, in a large breast cancer consortium with adequate statistical power, the variant was not associated with breast cancer risk overall, nor with risk of ER- breast cancer or TNBC, as previously hypothesized. IMPACT: Although the "Duffy-null" allele has been the focus of research as a contributor to aggressive breast cancer in Black women, this study with 34,930 cases and controls found no associations with risk.

Indexed as

Black or African AmericanBreast NeoplasmsCD8-Positive T-LymphocytesDuffy Blood-Group SystemReceptors, Cell SurfaceAdultAgedCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansMiddle AgedPolymorphism, Single NucleotideACKR1 protein, humanDuffy Blood-Group SystemReceptors, Cell Surface

Identifiers

PMID40627176
PMCPMC12337512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.